Clinical Trial Update: A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating MS-553 for chronic lymphocytic leukemia and small lymphocytic lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• MS-553 (MS-553)

Snippet

Sponsor: Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | Conditions: Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: TERMINATED